FDA approves first drug to prevent HIV infectionBMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e4879 (Published 17 July 2012) Cite this as: BMJ 2012;345:e4879
- Bob Roehr
- 1Washington, DC
The US Food and Drug Administration this week approved for the first time a drug for use in the prevention of HIV infection. The drug, Truvada, is one of the most commonly used components of an anti-HIV “cocktail” regimen in the United States and Europe.
Truvada is two drugs combined in a single pill, tenofovir disoproxil fumarate and emtricitabine. Its preventive use is commonly referred to as PrEP (pre-exposure prophylaxis). Studies in different groups at high risk of infection have shown its efficacy.1
It was approved “to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners,” said Debra Birnkrant in a telephone press conference with reporters. She is director …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial